Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, announced today it filed the first of several patent applications to cover their work on the use of CBD products for adjusting the microbial populations that live in humans.
The company is pioneering work based on profiling and modulating patient-derived microbiota, thus personalizing and profiling a person’s health status. This will make it possible to tailor and optimize treatments for patients.
The company aims to develop personalized anti-cancer and palliative treatments. Their R&D work is based in Israel, where it is licensed in both scientific and clinical research.
Its stock jumped 12% to $0.84 on the news. The company has a market cap of $99 million, making it roughly the 90th largest company in the cannabis sector.